Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
de Lédinghen V, Laforest C, Hézode C, Pol S, Renault A, Alric L, Larrey D, Métivier S, Tran A, Jézéquel C, Samuel D, Zoulim F, Tual C, Pailhé A, Gibowski S, Bourlière M, Bellissant E, Pawlotsky JM. de Lédinghen V, et al. Among authors: bellissant e. Clin Infect Dis. 2018 Mar 19;66(7):1013-1018. doi: 10.1093/cid/cix916. Clin Infect Dis. 2018. PMID: 29077864 Free article. Clinical Trial.
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
Roulot D, Thibault V, Laforest C, Fontaine H, Bronowicki JP, Asselah T, Bourlière M, Canva V, Leroy V, Loustaud-Ratti V, Ouzan D, Zoulim F, Schischmanoff O, Rousseau C, Renault A, Petrov-Sanchez V, Diallo A, Bellissant E, Serfaty L; ANRS HC32 QUATTRO study group. Roulot D, et al. Among authors: bellissant e. Eur J Gastroenterol Hepatol. 2018 Mar;30(3):302-309. doi: 10.1097/MEG.0000000000001035. Eur J Gastroenterol Hepatol. 2018. PMID: 29271782 Clinical Trial.
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
Rosenthal E, Fougerou-Leurent C, Renault A, Carrieri MP, Marcellin F, Garraffo R, Teicher E, Aumaitre H, Lacombe K, Bailly F, Billaud E, Chevaliez S, Dominguez S, Valantin MA, Reynes J, Naqvi A, Cotte L, Metivier S, Leroy V, Dupon M, Allegre T, De Truchis P, Jeantils V, Chas J, Salmon-Ceron D, Morlat P, Neau D, Perré P, Piroth L, Pol S, Bourlière M, Pageaux GP, Alric L, Zucman D, Girard PM, Poizot-Martin I, Yazdanpanah Y, Raffi F, Pabic EL, Tual C, Pailhé A, Amri I, Bellissant E, Molina JM; ANRS HC31 SOFTRIH Study Group. Rosenthal E, et al. Among authors: bellissant e. HIV Med. 2018 Mar;19(3):227-237. doi: 10.1111/hiv.12571. Epub 2017 Dec 7. HIV Med. 2018. PMID: 29214737 Free article. Clinical Trial.
Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM; ANRS HC27 BOCEPREVIH Study Group. Poizot-Martin I, et al. Among authors: bellissant e. HIV Clin Trials. 2016 Mar;17(2):63-71. doi: 10.1080/15284336.2015.1135553. Epub 2016 Feb 11. HIV Clin Trials. 2016. PMID: 27077673 Free article. Clinical Trial.
ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).
Kheloufi F, Poizot-Martin I, Garraffo R, Tavenard A, Quaranta S, Renault A, Lavrut T, Bourlière M, Halfon P, Piroth L, Bellissant E, Lacarelle B, Molina JM, Solas C; ANRS HC27 BOCEPREVIH Study Group. Kheloufi F, et al. Among authors: bellissant e. Antivir Ther. 2017;22(6):461-469. doi: 10.3851/IMP3074. Epub 2016 Sep 1. Antivir Ther. 2017. PMID: 27583701
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.
Kheloufi F, Bellissant E, Cotte L, Poizot-Martin I, Quaranta S, Garraffo R, Barrail-Tran A, Renault A, Fournier I, Lacarelle B, Bourlière M, Molina JM, Solas C; ANRS HC27 BOCEPREVIH & HC26 TELAPREVIH Study Groups. Kheloufi F, et al. Among authors: bellissant e. AIDS. 2016 Aug 24;30(13):2085-90. doi: 10.1097/QAD.0000000000001143. AIDS. 2016. PMID: 27149089
Impact of a targeted monitoring on data-quality and data-management workload of randomized controlled trials: A prospective comparative study.
Fougerou-Leurent C, Laviolle B, Tual C, Visseiche V, Veislinger A, Danjou H, Martin A, Turmel V, Renault A, Bellissant E. Fougerou-Leurent C, et al. Among authors: bellissant e. Br J Clin Pharmacol. 2019 Dec;85(12):2784-2792. doi: 10.1111/bcp.14108. Epub 2019 Dec 14. Br J Clin Pharmacol. 2019. PMID: 31471967 Free PMC article.
194 results